# LAI Intelligence Weekly v3 (Test Bench) – 2025-12-13

Newsletter generated in fallback mode (Bedrock error).

## Top Signals – LAI Ecosystem

**Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults**  
[Read more](https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf)

**Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)**  
[Read more](https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf)

**Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference**  
[Read more](https://www.medincell.com/wp-content/uploads/2025/11/MDC_Evercore-Piper_Sandler_EN_27112025.pdf)

**Medincell Awarded New Grant to Fight Malaria**  
[Read more](https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf)

**Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth**  
[Read more](https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf)

---

## Partnerships & Deals

---

## Regulatory Updates

---

## Clinical Updates

---

*Newsletter générée par Vectora Inbox – Powered by Amazon Bedrock*
